The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.

Thank you for being a part of the Cancer Survivor Network community. Survivors and caregivers like you have played a unique role in fostering an online environment that encourages connection among those needing support, community, and education. On May 28, the Network will be discontinued. More details are available here . If you have any questions, contact CSNSupportTeam@cancer.org. Thanks again for the support you’ve provided each other over the years. We remain committed to supporting you in other ways throughout your cancer journey.

10 yr. odds

nepol
nepol CSN Member Posts: 29
in Prostate Cancer #1

don't know to make it blue... the link...tinyurl.com/p8znv2m  good day to all      nepol

Like Care

Comments

  • Old Salt
    Old Salt CSN Member Posts: 1,741 Member
    #2
    Info to make a link

    has been carefully hidden. I don't know how either...

    Like Care
  • Old Salt
    Old Salt CSN Member Posts: 1,741 Member
    #3
    Here's the title of the paper (Thanks nepol)

    Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases

    In all, 40 (4.4%) of the 915 men survived for >10 years. Factors significantly associated with increased likelihood of surviving for >10 years in the univariate analyses were: absence of cancer-related pain; Eastern Cooperative Oncology Group (ECOG) performance status of <2; negligible analgesic consumption; T-category of 1–2; prostate-specific antigen (PSA) level of <231 μg/L; and a Soloway score of 1. In the multivariate analyses, ECOG performance status of <2, PSA level of <231 μg/L, and Soloway score of 1, were all independent predictors of long-term survival. All subscales of the EORTC-C30 were higher in this group than for patients with short survival, but slowly declined over the decade.

    Conclusion


    A subgroup of patients with prostate cancer with M1b disease and certain characteristics showed a positive long-term response to androgen-deprivation therapy with an acceptable QoL over a decade or more. Independent predictors of long-term survival were identified as ECOG performance status of <2, limited extent of bone metastases (Soloway score of 1), and a PSA level of <231 μg/L at the time of enrolment.


    Like Care

Discussion Boards